ASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018
|
|
- Allyson Gray
- 5 years ago
- Views:
Transcription
1 ASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018
2 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of The audience is cautioned that such forward looking statements involve risks and uncertainties, including those described in our annual report filed on form 10-K for the year ended June 30, 2017, and other filings of the Company with the Securities and Exchange Commission, which may cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.
3 Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A. Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty 3
4 Background BRAFi/MEKi combinations are established as a standard of care for the treatment of advanced BRAF V600 -mutant melanoma with median PFS ( 12 months) and OS ( 24 months) 1-3 Approved combinations have unique toxicities that may impact the ability to deliver optimal treatment Dabrafenib/trametinib is associated with pyrexia 2,3 Vemurafenib/cobimetinib is associated with photosensitivity 4 ENCO has a unique pharmacologic profile with an on-target dissociation half-life of >30 hours, leading to sustained target inhibition 5 BINI has a shorter half-life than other MEKi; dose modification may be easier 6 Promising clinical activity and tolerability were demonstrated with ENCO + BINI in a phase 1b/II study 5,7 BINI=binimetinib; BRAFi=BRAF inhibitor; ENCO=encorafenib; MEKi=MEK inhibitor; OS=overall survival; PFS=progression-free survival 1. Chapman PB, et al. N Engl J Med. 2011;364(26): Robert C, et al. N Engl J Med. 2015;372(1): Long GV, et al. Lancet. 2015;386(9992): Ascierto PA, et al. Lancet Oncol. 2016;17: Delord JP, et al. Clin Cancer Res. 2017;23: Data on File. Array BioPharma Inc. 7. Sullivan RJ, et al. J Clin Oncol. 2015;33:
5 Study Design and Objectives COLUMBUS Part 1 Untreated or progressed on/after prior first-line immunotherapy BRAF V600E and/or BRAF V600K ECOG PS 0 1 R 1:1:1 (N=577) Encorafenib 450 mg QD + Binimetinib 45 mg BID (n=192) Vemurafenib 960 mg BID (n=191) Encorafenib 300 mg QD (n=194) COLUMBUS Part 2* R 3:1 (N=344) COMBO300 Encorafenib 300 mg QD + Binimetinib 45 mg BID (n=258) Encorafenib 300 mg QD (n=86) Efficacy update with additional follow-up of 18 months: OS: Secondary endpoint Planned after 232 events in the and groups combined Median duration of follow-up : 36.8 months PFS: Primary endpoint Median duration of follow-up : 32.1 months =encorafenib 450 mg QD + binimetinib 45 mg BID; ECOG PS=Eastern Cooperative Oncology Group performance status; OS=overall survival; PFS=progression-free survival; R=randomization; =vemurafenib 960 mg BID. *Amendment requested by FDA. Included in hierarchical testing approach. Median follow-up of patients assessed using reverse Kaplan-Meier approach (i.e. median potential follow-up). 5
6 Progression-Free Survival (%) Study Design and Objectives COLUMBUS Part 1 Untreated or progressed on/after prior first-line immunotherapy BRAF V600E and/or BRAF V600K ECOG PS 0 1 R 1:1:1 (N=577) Encorafenib 450 mg QD + Binimetinib 45 mg BID (n=192) Vemurafenib 960 mg BID (n=191) Encorafenib 300 mg QD (n=194) Median PFS in months (95% CI) 14.9 ( ) 7.3 ( ) HR (95% CI), 0.54 ( ) P< Time (mo) Dummer, R et al. Lancet Oncol. 2018; 19(5): Efficacy update with additional follow-up of 18 months: OS: Secondary endpoint Planned after 232 events in the and groups combined Median duration of follow-up : 36.8 months PFS: Primary endpoint Median duration of follow-up : 32.1 months =encorafenib 450 mg QD + binimetinib 45 mg BID; ECOG PS=Eastern Cooperative Oncology Group performance status; OS=overall survival; PFS=progression-free survival; R=randomization; =vemurafenib 960 mg BID. *Amendment requested by FDA. Included in hierarchical testing approach. Median follow-up of patients assessed using reverse Kaplan-Meier approach (i.e. median potential follow-up). 6
7 Patient Disposition Variable, % n=192 n=194 n=191 Untreated 0 1% 3% Discontinued treatment 78% 87% 91% Progressive disease 52% 52% 57% Adverse event 10% 13% 13% Physician or patient decision* 10% 21% 18% Death 4% 1% 2% Other 1% 1% 1% Treatment ongoing 22% 12% 7% =encorafenib 450 mg QD + binimetinib 45 mg BID; =encorafenib 300 mg QD; =vemurafenib 960 mg BID. *Physician or patient/guardian decision. Includes protocol violation, lost to follow-up, and new therapy for study indication. As of the data cutoff date of November 7,
8 Baseline Characteristics Characteristic n=192 n=194 n=191 Median age (range), years 57 (20 89) 54 (23 88) 56 (21 82) Male sex 60% 56% 58% ECOG performance status 0 71% 72% 73% LDH > ULN 29% 24% 27% LDH ULN 71% 76% 73% BRAF mutation status (BRAF V600E /BRAF V600K ) 89%/12% 89%/10% 88%/12% Tumor stage at study entry IIIB/IIIC 5% 3% 6% IVM1a 14% 15% 13% IVM1b 18% 20% 16% IVM1c 64% 62% 65% Number of organs involved 1 25% 29% 24% 2 30% 27% 31% 3 45% 44% 46% =encorafenib 450 mg QD + binimetinib 45 mg BID; ECOG=Eastern Cooperative Oncology Group; =encorafenib 300 mg QD; LDH=lactate dehydrogenase; ULN=upper limit of normal; =vemurafenib 960 mg BID. 8
9 Previous Immunotherapy Adjuvant/neoadjuvant settings n=192 n=194 n=191 Ipilimumab* 1% 1% 1% Interferons/interleukins Adjuvant 24% 24% 24% Neoadjuvant 0 1% 1% Advanced/metastatic settings n=192 n=194 n=191 Ipilimumab* 3% 5% 3% Anti PD-1 or anti PD-L1*, 1% 1% 0 Interferons/interleukins 2% 2% 3% =encorafenib 450 mg QD plus binimetinib 45 mg BID; =encorafenib 300 mg QD; PD-1=programmed death 1; PD-L1=programmed death ligand 1; =vemurafenib 960 mg BID. *A patient may have received ipilimumab and anti PD1/PD-L1 in combination. Includes interferon, interferon α, interferon α-2a, interferon α-2b, and interferon β. Nivolumab. Includes interferon, interferon α-2b, and interleukin-2. 9
10 Systemic Treatment Following Study Drug Discontinuation Treatment received after study drug* n=192 n=194 n=191 Any treatment 42% 56% 62% Anti PD-1/anti PD-L1 20% 21% 25% Anti CTLA-4 17% 16% 19% Anti CTLA-4 + anti PD-1/anti PD-L1 3% 2% 2% BRAFi + MEKi 5% 14% 20% BRAFi 6% 8% 13% Chemotherapy 7% 12% 12% Other 3% 2% 7% BRAFi=BRAF inhibitor; =encorafenib 450 mg QD + binimetinib 45 mg BID; CTLA-4=cytotoxic T-lymphocyte-associated protein 4; =encorafenib 300 mg QD; MEKi=MEK inhibitor; PD-1=programmed death 1; PD-L1=programmed death ligand 1; =vemurafenib 960 mg BID. *Multiple uses of a therapy in a single patient were only counted once in the frequency for that category of therapy; patients who received multiple categories of therapy are counted in each respective row. 10
11 Use of Checkpoint Inhibitors as First Post-Study Treatment Treatment received after study drug* n=192 n=194 n=191 Anti PD-1/anti PD-L1 20% 21% 25% Used first after study drug 12% 14% 13% Anti CTLA-4 17% 16% 19% Used first after study drug 15% 13% 15% Anti CTLA-4 + anti PD-1/anti PD-L1 3% 2% 2% Used first after study drug 2% 0 1% =encorafenib 450 mg QD + binimetinib 45 mg BID; CTLA-4=cytotoxic T-lymphocyte-associated protein 4; =encorafenib 300 mg QD; PD-1=programmed death 1; PD-L1=programmed death ligand 1; =vemurafenib 960 mg BID. *Multiple uses of a therapy in a single patient were only counted once in the frequency for that category of therapy; patients who received multiple categories of therapy are counted in each respective row. 11
12 Overall Survival, % Overall Survival: vs Median OS in months (95% CI) 33.6 ( ) 16.9 ( ) HR (95% CI), 0.61 ( ) Nominal 2-sided P< Censored patients Patients at risk Time (months) =encorafenib 450 mg QD + binimetinib 45 mg BID; HR=hazard ratio; OS=overall survival; =vemurafenib 960 mg BID. 12
13 Overall Survival, % Overall Survival Landmark Data: vs : 76% : 63% : 58% : 43% : 47%* : 32% Censored patients Patients at risk Time (months) =encorafenib 450 mg QD + binimetinib 45 mg BID; =vemurafenib 960 mg BID. *3-year rates are not fully mature. 13
14 Overall Survival in Subgroups: vs Subgroup No. of Events/Patients Hazard Ratio (95%CI) All patients 232/ ( ) Sex Male Female 144/226 88/ ( ) 0.57 ( ) Age < /272 68/ ( ) 0.71 ( ) BRAF mutation V600E V600K 208/338 24/ ( ) 0.31 ( ) LDH ULN >ULN 140/276 92/ ( ) 0.95 ( ) ECOG PS=0 PS=1 158/279 74/ ( ) 0.53 ( ) Tumor stage IIIb, IIIc, IVM1a,or IVM1b IVM1c 88/ / ( ) 0.59 ( ) No. of organs involved at baseline >3 42/92 67/117 57/87 66/ ( ) 0.63 ( ) 0.50 ( ) 0.85 ( ) Better Better =encorafenib 450 mg QD + binimetinib 45 mg BID; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; PS=performance status; ULN=upper limit of normal; =vemurafenib 960 mg BID. 14
15 Overall Survival, % Overall Survival: vs Median OS in months (95% CI) 33.6 ( ) 23.5 ( ) HR (95% CI), 0.81 ( ) Nominal 2-sided P= Censored patients Patients at risk Time (months) =encorafenib 450 mg QD + binimetinib 45 mg BID; =encorafenib 300 mg QD; HR=hazard ratio; OS=overall survival. 15
16 Overall Survival, % Overall Survival: vs Median OS in months (95% CI) 23.5 ( ) 16.9 ( ) HR (95% CI), 0.76 ( ) Nominal 2-sided P=0.033 Patients at risk Censored patients Time (months) =encorafenib 300 mg QD; HR=hazard ratio; OS=overall survival; =vemurafenib 960 mg BID. 16
17 Progression-Free Survival, % Updated Progression-Free Survival: vs Median PFS in months (95% CI) 14.9 ( ) 7.3 ( ) HR (95% CI), 0.51 ( ) Nominal 2-sided P< Censored patients Patients at risk Time (months) =encorafenib 450 mg QD + binimetinib 45 mg BID; HR=hazard ratio; PFS=progression-free survival; =vemurafenib 960 mg BID. 17
18 Progression-Free Survival, % Updated Progression-Free Survival Landmark Data: vs : 56% : 33% : 37% : 20% : 28%* : 13%* Censored patients Patients at risk Time (months) =encorafenib 450 mg QD + binimetinib 45 mg BID; =vemurafenib 960 mg BID. *3-year rates are not fully mature and are based on small numbers of patients at risk. 18
19 Progression-Free Survival, % Progression-Free Survival, % Updated Progression-Free Survival Censored patients Patients at risk Time (months) vs Median PFS in months (95% CI) 9.6 ( ) 7.3 ( ) HR (95% CI), 0.68 ( ) Nominal 2-sided P= Median PFS in months (95% CI) 14.9 ( ) 9.6 ( ) HR (95% CI), 0.77 ( ) Nominal 2-sided P= =encorafenib 450 mg QD + binimetinib 45 mg BID; =encorafenib 300 mg QD; HR=hazard ratio; PFS=progression-free survival; =vemurafenib 960 mg BID vs Censored patients Time (months) Patients at risk
20 Confirmed Response Rates Confirmed Response n=192 n=194 n=191 Central Review Local Review Central Review Local Review Central Review Local Review ORR (95% CI)* 64% (57 70) 76% (69 81) 52% (44 59) 58% (50 65) 41% (34 48) 49% (42 57) CR 11% 19% 7% 10% 8% 8% PR 52% 56% 44% 48% 32% 41% Median DOR (95% CI), mo 18.6 ( ) 16.2 ( ) 15.2 ( ) 14.8 ( ) 12.3 ( ) 7.7 ( ) SD 29% 17% 32% 29% 40% 35% PD 8% 7% 16% 13% 19% 16% DCR (95% CI) 92% (87 96) 93% (88 96) 84% (78 89) 87% (81 91) 81% (75 86) 84% (78 89) =encorafenib 450 mg QD + binimetinib 45 mg BID; CR=complete response; DCR=disease control rate; DOR=duration of response; =encorafenib 300 mg QD; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease; =vemurafenib 960 mg BID. *ORR = CR + PR. Includes patients with only non-target lesions with best response of non-cr/non-pd. Includes patients with best response of unknown or no assessment. DCR = CR + PR + SD. 20
21 Confirmed Response Rates Confirmed Response n=192 n=194 n=191 Central Review Local Review Central Review Local Review Central Review Local Review ORR (95% CI)* 64% (57 70) 76% (69 81) 52% (44 59) 58% (50 65) 41% (34 48) 49% (42 57) CR 11% 19% 7% 10% 8% 8% PR 52% 56% 44% 48% 32% 41% Median DOR (95% CI), mo 18.6 ( ) 16.2 ( ) 15.2 ( ) 14.8 ( ) 12.3 ( ) 7.7 ( ) SD 29% 17% 32% 29% 40% 35% PD 8% 7% 16% 13% 19% 16% DCR (95% CI) 92% (87 96) 93% (88 96) 84% (78 89) 87% (81 91) 81% (75 86) 84% (78 89) =encorafenib 450 mg QD + binimetinib 45 mg BID; CR=complete response; DCR=disease control rate; DOR=duration of response; =encorafenib 300 mg QD; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease; =vemurafenib 960 mg BID. *ORR = CR + PR. Includes patients with only non-target lesions with best response of non-cr/non-pd. Includes patients with best response of unknown or no assessment. DCR = CR + PR + SD. 21
22 Confirmed Response Rates Confirmed Response n=192 n=194 n=191 Central Review Local Review Central Review Local Review Central Review Local Review ORR (95% CI)* 64% (57 70) 76% (69 81) 52% (44 59) 58% (50 65) 41% (34 48) 49% (42 57) CR 11% 19% 7% 10% 8% 8% PR 52% 56% 44% 48% 32% 41% Median DOR (95% CI), mo 18.6 ( ) 16.2 ( ) 15.2 ( ) 14.8 ( ) 12.3 ( ) 7.7 ( ) SD 29% 17% 32% 29% 40% 35% PD 8% 7% 16% 13% 19% 16% DCR (95% CI) 92% (87 96) 93% (88 96) 84% (78 89) 87% (81 91) 81% (75 86) 84% (78 89) =encorafenib 450 mg QD + binimetinib 45 mg BID; CR=complete response; DCR=disease control rate; DOR=duration of response; =encorafenib 300 mg QD; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease; =vemurafenib 960 mg BID. *ORR = CR + PR. Includes patients with only non-target lesions with best response of non-cr/non-pd. Includes patients with best response of unknown or no assessment. DCR = CR + PR + SD. 22
23 Confirmed Response Rates Confirmed Response n=192 n=194 n=191 Central Review Local Review Central Review Local Review Central Review Local Review ORR (95% CI)* 64% (57 70) 76% (69 81) 52% (44 59) 58% (50 65) 41% (34 48) 49% (42 57) CR 11% 19% 7% 10% 8% 8% PR 52% 56% 44% 48% 32% 41% Median DOR (95% CI), mo 18.6 ( ) 16.2 ( ) 15.2 ( ) 14.8 ( ) 12.3 ( ) 7.7 ( ) SD 29% 17% 32% 29% 40% 35% PD 8% 7% 16% 13% 19% 16% DCR (95% CI) 92% (87 96) 93% (88 96) 84% (78 89) 87% (81 91) 81% (75 86) 84% (78 89) =encorafenib 450 mg QD + binimetinib 45 mg BID; CR=complete response; DCR=disease control rate; DOR=duration of response; =encorafenib 300 mg QD; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease; =vemurafenib 960 mg BID. *ORR = CR + PR. Includes patients with only non-target lesions with best response of non-cr/non-pd. Includes patients with best response of unknown or no assessment. DCR = CR + PR + SD. 23
24 Confirmed Response Rates Confirmed Response n=192 n=194 n=191 Central Review Local Review Central Review Local Review Central Review Local Review ORR (95% CI)* 64% (57 70) 76% (69 81) 52% (44 59) 58% (50 65) 41% (34 48) 49% (42 57) CR 11% 19% 7% 10% 8% 8% PR 52% 56% 44% 48% 32% 41% Median DOR (95% CI), mo 18.6 ( ) 16.2 ( ) 15.2 ( ) 14.8 ( ) 12.3 ( ) 7.7 ( ) SD 29% 17% 32% 29% 40% 35% PD 8% 7% 16% 13% 19% 16% DCR (95% CI) 92% (87 96) 93% (88 96) 84% (78 89) 87% (81 91) 81% (75 86) 84% (78 89) =encorafenib 450 mg QD + binimetinib 45 mg BID; CR=complete response; DCR=disease control rate; DOR=duration of response; =encorafenib 300 mg QD; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease; =vemurafenib 960 mg BID. *ORR = CR + PR. Includes patients with only non-target lesions with best response of non-cr/non-pd. Includes patients with best response of unknown or no assessment. DCR = CR + PR + SD. 24
25 Confirmed Response Rates Confirmed Response n=192 n=194 n=191 Central Review Local Review Central Review Local Review Central Review Local Review ORR (95% CI)* 64% (57 70) 76% (69 81) 52% (44 59) 58% (50 65) 41% (34 48) 49% (42 57) CR 11% 19% 7% 10% 8% 8% PR 52% 56% 44% 48% 32% 41% Median DOR (95% CI), mo 18.6 ( ) 16.2 ( ) 15.2 ( ) 14.8 ( ) 12.3 ( ) 7.7 ( ) SD 29% 17% 32% 29% 40% 35% PD 8% 7% 16% 13% 19% 16% DCR (95% CI) 92% (87 96) 93% (88 96) 84% (78 89) 87% (81 91) 81% (75 86) 84% (78 89) =encorafenib 450 mg QD + binimetinib 45 mg BID; CR=complete response; DCR=disease control rate; DOR=duration of response; =encorafenib 300 mg QD; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease; =vemurafenib 960 mg BID. *ORR = CR + PR. Includes patients with only non-target lesions with best response of non-cr/non-pd. Includes patients with best response of unknown or no assessment. DCR = CR + PR + SD. 25
26 Overall Summary of Safety Event n=192 Median Duration of Exposure: 51 weeks n=192 Median Duration of Exposure: 31 weeks n=186 Median Duration of Exposure: 26 weeks Adverse events 98% 99% 100% Grade 3/4 adverse events 64% 67% 66% Adverse events leading to discontinuation Adverse events leading to dose reduction/interruption 15% 15% 17% 53% 71% 62% On-treatment deaths* 12% 8% 11% =encorafenib 450 mg QD + binimetinib 45 mg BID; =encorafenib 300 mg QD; =vemurafenib 960 mg BID. *Includes on-treatment deaths and deaths within 30 days of stopping study treatment. 26
27 Patient (%) Groupings of AEs Associated With BRAFi and MEKi Initial analysis Updated analysis Initial analysis Updated analysis Initial analysis Updated analysis Rash Serous retinopathy Pyrexia Transaminases increased Skin papilloma LVD Photosensitivity CuSCC Dermatitis acneiform BCC Increased bilirubin Terms represent groupings of similar or related adverse events. BCC=basal cell carcinoma; BRAFi=BRAF inhibitor; =encorafenib 450 mg QD + binimetinib 45 mg BID; CuSCC=cutaneous squamous cell carcinoma; =encorafenib 300 mg QD; LVD=left ventricular dysfunction; MEKi=MEK inhibitor; =vemurafenib 960 mg BID. 27
28 Conclusions showed improved OS vs : 33.6 mo vs 16.9 mo (HR 0.61; nominal 2-sided P<0.0001) Updated PFS results remained the same as previously reported: median PFS 14.9 mo 1 Performance of in COLUMBUS was consistent with historical data for ORR, PFS, and OS 2,3 Use of subsequent systemic therapies in COLUMBUS was similar to phase 3 studies of established BRAFi/MEKi therapies 2,4 showed a favorable tolerability profile and no new safety concerns Encorafenib plus binimetinib combination therapy provides a new efficacy benchmark for targeted therapy and it is a promising treatment option for patients with BRAF V600 -mutant melanoma BRAFi=BRAF inhibitor; =encorafenib 450 mg QD + binimetinib 45 mg BID; HR=hazard ratio; MEKi=MEK inhibitor; OS=overall survival; PFS=progression-free survival; =vemurafenib 960 mg BID. 1. Dummer R, et al. Lancet Oncol. 2018;19: Robert C, et al. Eur J Cancer. 2015;51:S663-S Ascierto PA, et al. Lancet Oncol. 2016;17: Long GV, et al. Ann Oncol. 2017;28:
29 Acknowledgments The authors thank the patients, their families, and the sites participating in this study. This study was sponsored by Array BioPharma Inc., with funding support from Novartis Pharmaceuticals Corporation. 29
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala,
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationRESULTS OF COLUMBUS PART 2: A Phase 3 Trial of Encorafenib Plus Binimetinib Versus Encorafenib in BRAF-Mutant Melanoma
RESULTS OF COLUMBUS PART 2: A Phase 3 Trial of Encorafenib Plus Binimetinib Versus Encorafenib in BRAF-Mutant Melanoma Reinhard Dummer, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationArticles. Funding Array BioPharma, Novartis. Copyright 2018 Elsevier Ltd. All rights reserved.
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Reinhard Dummer*, Paolo A Ascierto*,
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationArray BioPharma Third Quarter of F2018 Update MAY 9, 2018
Array BioPharma Third Quarter of F2018 Update MAY 9, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the
More informationESMO GI / BEACON CRC SAFETY LEAD-IN ENCORE PRESENTATION June 23, 2018
ESMO GI / BEACON CRC SAFETY LEAD-IN ENCORE PRESENTATION June 23, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationCutaneous melanoma: new developments for 2018
Cutaneous melanoma: new developments for 2018 and beyond KIM MARGOLIN, M.D., FASCO CITY OF HOPE MEDICAL ONCOLOGY CORONADO, CALIFORNIA SEPTEMBER 20, 2018 DISCLOSURE Consultant for ImaginAb, Nektar Therapeutics,
More informationAmerikanischer Krebskongress 2018
Congress-Lightning Amerikanischer Krebskongress 218 Dermatoonkologie Prof. Dr. Ralf Gutzmer, Hannover Melanom adjuvant Melanom palliativ Nicht-melanozytäre Hauttumore Adjuvant Therapy With Nivolumab Versus
More informationArray BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016
Array BioPharma Jefferies 216 Global Healthcare Conference June 9, 216 Safe Harbor Statement 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationEric Van Cutsem University Hospitals Leuven, Belgium
BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti Epidermal Growth Factor Receptor Antibody Cetuximab for BRAF V600E Metastatic Colorectal
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationInitial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma
Initial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma Reinhard Dummer, 1 Caroline Robert, 2 Marta Nyakas, 3 Grant McArthur,
More informationAxel Grothey West Cancer Center University of Tennessee, Germantown, TN, USA
Updated Results of the BEACON CRC Safety Lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mcrc) Axel Grothey West Cancer Center University
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationThe information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information
The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationMelanoma in 2017 Immunotherapy versus targeted therapy. Assoc. Prof Victoria Atkinson
Melanoma in 2017 Immunotherapy versus targeted therapy Assoc. Prof Victoria Atkinson Disclosures Advisory Board- BMS, MSD, Novartis, Pierre Fabre Speakers Fees- BMS, MSD, Novartis, Roche Travel Support-BMS
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer Jefferies 2015 Healthcare Conference Ron Squarer, Chief Executive Officer November 19, 2015 Safe Harbor Statement Forward-looking statements
More informationArray BioPharma. October 30, > First Quarter F2019 Update
Array BioPharma October 30, 2018 > First Quarter F2019 Update 1 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationResults of NEMO: A Phase 3 Trial of Binimetinib (BINI) vs Dacarbazine (DTIC) in NRAS-Mutant Cutaneous Melanoma
Results of NEMO: A Phase 3 Trial of Binimetinib (BINI) vs Dacarbazine (DTIC) in NRAS-Mutant Cutaneous Melanoma Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Arance, Caroline Dutriaux, Michele
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationOutcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors Allison Ackerman, MD, PhD 1 ; Oliver Klein, MD 2 ; David F. McDermott, MD 1 ; Wei Wang, PhD 3
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationWhat s new in melanoma? Combination!
DOI 10.1186/s12967-015-0582-1 EDITORIAL Open Access What s new in melanoma? Combination! Paolo A Ascierto 1*, Francesco M Marincola 2 and Michael B Atkins 3 Abstract Melanoma was again a focus of attention
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationBRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2018 Origination: 4/2013 Next Review: 12/2019 Policy Blue Cross and Blue Shield
More informationUpdates in Metastatic Melanoma
SCSHP 214 Annual Meeting Updates in Metastatic Melanoma LeAnn B. orris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of Pharmacy Background Estimated 76,69 new cases in 213 Increasing
More informationBeyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma:
Beyond BRAFi/MEKi: Combination and Sequencing Approaches for in Patients with Metastatic BRAF V600 Mutant Melanoma: Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationMalignant Melanoma, what s new? Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Malignant Melanoma, what s new? Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Melanoma Epidemiology: Incidence and Mortality Estimated 2012 Global Incidence and Mortality by WHO Region (all
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationSupplementary Online Content
Supplementary Online Content Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non small cell lung
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationMelanoma: novità ESMO 2017
Melanoma: novità ESMO 2017 Vincenzo Picone Istituto dermopatico dell Immacolata (IDI) AGENDA Metastatico CheckMate 067 Adiuvante LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK
More informationMelanoma BRAF mutado y terapias dirigidas. Javier Medina Martínez Hospital Virgen de la Salud, Toledo
Melanoma BRAF mutado y terapias dirigidas Javier Medina Martínez Hospital Virgen de la Salud, Toledo Enfermedad avanzada: Seguimiento a largo plazo Retratamiento Metástasis cerebrales Adyuvancia November-2017
More informationBreakthrough and Landscape of Acral and Mucosal Melanomas. Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute
Breakthrough and Landscape of Acral and Mucosal Melanomas Jun Guo. M.D., Ph.D Peking University Cancer Hospital & Institute Current status of advanced melanoma Current status of advanced MM Targeted therapy
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationNew treatments in melanoma
New treatments in melanoma Paolo A. Ascierto, MD Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationHistology independent indications in oncology. The BRAF Story. Yibing Yan PhD Roche / Genentech
Histology independent indications in oncology The BRAF Story Yibing Yan PhD Roche / Genentech 1 Introduction the discovery Case study in BRAF mutant melanoma heterogeneity within the tumour variability
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationvemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd.
Resubmission vemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd. 08 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationKEYNOTE 695: TAVO Phase 2b Melanoma Trial Preliminary Data for SITC November 6, 2018
KEYNOTE 695: TAVO Phase 2b Melanoma Trial Preliminary Data for SITC 2018 November 6, 2018 1 FORWARD-LOOKING STATEMENTS To the extent statements contained in the following presentations are not descriptions
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)
A service of the U.S. National Institutes of Health Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial
More informationMelanoma brain mets management
Melanoma brain mets management Reinhard Dummer, Phil Cheng, Simone Goldinger, Katrin Kerl, Lars French, Joanna Mangana, Lukas Sommer, Ralph Braun, Mitch Levesque Substantially worse survival in patients
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationRoche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides
More informationARRAY BioPharma. September > Founded on Science, Focused on Patients
ARRAY BioPharma September 2018 > Founded on Science, Focused on Patients 1 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationINIBITORE di BRAF nel MELANOMA
INIBITORE di BRAF nel MELANOMA Paola Agnese Cassandrini Negrar,29 novembre 2016 BRAF is a serine/threonine protein kinasi encoded on chromosome 7q34 that activates the MAP kinase/erksegnaling pathway
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationBRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma
QUALITY OF LIFE IN ONCOLOGY Review article BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma Maksymilian Kruczała, Aleksandra Grela-Wojewoda, Marek Ziobro Clinic of Systemic and Metastatic
More informationIneffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
Amini-Adle et al. BMC Cancer (2018) 18:705 https://doi.org/10.1186/s12885-018-4618-9 RESEARCH ARTICLE Open Access Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma M. Amini-Adle
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationUpdate on Melanoma. Main Themes
Update on Melanoma Antoni Ribas, M.D. Professor of Medicine, Surgery, and Medical and Molecular Pharmacology University of California Los Angeles (UCLA) and the Jonsson Comprehensive Cancer Center Main
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More information